Assembly Biosciences, Inc.
corporate_fare Company Profile
Assembly Biosciences, Inc. (NASDAQ:ASMB) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 20 items for ASMB at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-12, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 11 rated 8 or above. Recent SEC coverage for ASMB spans 8-K, SCHEDULE 13D/A, 424B5, 10-Q.
Recent high-impact activity:
- Assembly Bio Q3 Loss Widens to $20.3M; Gilead $75M Fee Extends Runway Into 2029
- Assembly Bio Posts $20.3M Q3 Loss, Secures $75M Gilead Fee and 2029 Runway
- Assembly Bio's ABI-6250 Shows Clean Safety and Target Engagement in Phase 1a
- Assembly Bio Exercises Profit-Share Option on Gilead Herpes Program, Secures $75M Payment
- Assembly Bio Q2 Loss Narrows to $3.9M; Cash Runway Extended into 2029
Financial Snapshot
Short Interest & Short Volume
17.00 days to coverFINRA reported short interest of 3,032,675 shares in ASMB as of the October 30, 2026 settlement, a 4.1% increase from the prior period — about 17.0 days to cover at its recent average daily volume. On November 20, 2026, 68.4% of ASMB volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.